Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Rosindol: A fluorogen for the quantitative measurement of reactive oxygen species in living cells.

bioRxiv : the preprint server for biology·2026
Same author

Coil-Tag Conjugation: A Next Gen Site-Specific ADC Fabrication Technology.

Bioconjugate insights·2026
Same author

Peptide Tag-nology for Preparation of Site-Specific Antibody-Drug Conjugates.

Bioconjugate chemistry·2026
Same author

Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearance.

bioRxiv : the preprint server for biology·2026
Same author

A 3D microfluidic model of exchange between perfused blood and lymphatic microvascular networks.

Lab on a chip·2026
Same author

Supramolecular coiled-coil peptide platform for site-specific antibody drug conjugate engineering.

Nature communications·2026

相关实验视频

Updated: Feb 28, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

基于RNA的自我放大CAR T细胞疗法,具有增长的持续时间和多基因逻辑功能的功能.

Yuyang Gu, Jaehoon Choi, Devin Mutha

    bioRxiv : the preprint server for biology
    |February 27, 2026
    PubMed
    概括

    自放大RNA (saRNA) CAR T细胞为治疗血液癌症提供了比传统的病毒载体方法更安全,更有效的替代方案. 这种新型的saRNA平台增强了CAR T细胞的耐用性和瘤控制,改善了患者的治疗结果.

    科学领域:

    • 免疫治疗是一种免疫疗法.
    • 分子生物学分子生物学
    • 在瘤学瘤学.

    背景情况:

    • 化学抗原受体T (CAR-T) 细胞疗法是血液恶性瘤的有希望的治疗方法.
    • 目前使用病毒载体制造的CAR-T是昂贵的,耗时的,并带有插入性突变发生等风险.
    • 传递 RNA (mRNA) CAR T 细胞提供了更好的安全性和速度,但由于表达时间短,需要频繁的剂量.

    研究的目的:

    • 开发和评估用于CAR T细胞工程的修改自放大RNA (saRNA) 平台.
    • 与mRNA CAR T细胞相比,评估saRNA CAR T细胞的疗效和耐用性.
    • 探索saRNA在高级CAR T细胞设计中的潜力.

    主要方法:

    • 工程CAR T细胞使用修改的自我放大RNA (saRNA) 平台.
    • 在急性淋巴细胞白血病 (ALL) 异种移植模型中评估saRNA CAR T细胞的性能.
    • 评估saRNA的共同表达能力,用于先进的CAR系统.

    主要成果:

    • 与mRNA CAR T细胞相比,saRNA CAR T细胞表现出长时间的CAR表达和增强瘤控制的耐久性.
    • 在使用saRNA CAR T细胞的ALL异种移植模型中观察到优异的瘤抑制和延长的存活率.

    更多相关视频

    Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
    06:10

    Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

    Published on: May 9, 2025

    1.0K
    Generation of Human Chimeric Antigen Receptor Regulatory T Cells
    10:29

    Generation of Human Chimeric Antigen Receptor Regulatory T Cells

    Published on: January 3, 2025

    2.5K

    相关实验视频

    Last Updated: Feb 28, 2026

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
    09:56

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

    Published on: February 21, 2025

    1.5K
    Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
    06:10

    Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

    Published on: May 9, 2025

    1.0K
    Generation of Human Chimeric Antigen Receptor Regulatory T Cells
    10:29

    Generation of Human Chimeric Antigen Receptor Regulatory T Cells

    Published on: January 3, 2025

    2.5K
  • 该saRNA平台成功实现了多种蛋白质的共同表达,用于高级CAR设计,如逻辑门的CAR T细胞.

    • 结论:

    • 修改后的saRNA平台为CAR T细胞工程提供了一种强大而通用的方法.
    • saRNA CAR T细胞在癌症治疗中具有有利的安全性,有效性和可访问性.
    • 这项技术有可能推进血液性恶性瘤及其他疾病的CAR T细胞疗法.